ACLA News
-
ACLA Expands Policy, Government Affairs Teams with Joan Kegerize, Liz Thomas
Kegerize to help lead ACLA’s policy work related to reimbursement & scientific affairs; Thomas to support industry’s broader advocacy and federal affairs priorities Washington, D.C. – The American Clinical Laboratory Association (ACLA) today announced two new additions to the Association’s policy and advocacy teams. Joan Kegerize, who previously served as a principal consultant for GMBI Consulting, will serve as Vice President of Reimbursement andContinue Reading »... -
ACLA Appellant/Petitioner Brief: American Clinical Laboratory Association v. Alex Azar
... -
ACLA Urges Congressional Leaders to Advance New Regulatory Framework for Diagnostic Tests
In Comments to Congress, ACLA Cites Concerns with the FDA’s New Proposals for Diagnostic Reform Washington, D.C. – Today, the American Clinical Laboratory Association (ACLA) calls on Congressional leaders to enact a distinct regulatory framework for diagnostics – a key goal outlined in comments to Reps. Larry Bucshon (R-IN) and Diana DeGette (D-CO), and Sens. Orrin Hatch (R-UT) and Michael Bennet (D-CO). The commentsContinue Reading »... -
Stakeholder Letter on Diagnostic Reform
... -
ACLA Urges Summary Judgment from District Court on Lawsuit Against HHS
Lawsuit targets HHS’ unlawful implementation of 2014 Medicare legislation, regulation that would jeopardize beneficiaries’ access to critical lab services Washington, D.C. – With millions of Medicare beneficiaries facing potential shortages in critical laboratory tests and diagnostics, the American Clinical Laboratory Association (ACLA) continued the push for summary judgment in its lawsuit against the U.S. Department of Health and Human Services (HHS) for failing toContinue Reading »... -
ACLA VS. AZAR – Reply in Support of Motion for Summary Judgment
... -
ACLA Supportive of CMS Revisions to National Coverage Determination on the Use of Next Generation Sequencing in Cancer
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) expressed support today for revisions made by the Centers for Medicare and Medicaid Services (CMS) to the final National Coverage Determination (NCD) released today on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer. The association and other stakeholders submitted extensive comments to the agency on the proposed NCD to ensure that the policyContinue Reading »... -
ACLA Evaluating CMS’ Final National Coverage Determination on Next Generation Sequencing
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) stated that it is reviewing the Centers for Medicare & Medicaid Services (CMS) final National Coverage Determination (NCD) released today on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer. The association had previously voiced concerns in response to the proposed NCD, cautioning that it would deprive Medicare beneficiaries of access to critical laboratoryContinue Reading »... -
ACLA Letter to CMS Administrator Seema Verma on Medicaid Rates
... -
Policymakers, Patient Advocates, and Clinical Laboratory Leaders Discuss the Future of Clinical Laboratory Testing at ACLA’s 23rd Annual Meeting
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) today held its 2018 annual meeting, convening policymakers, patient advocates, payers and industry leaders to discuss the future of clinical laboratory testing. The annual conference, now in its twenty-third year, is the premier meeting in Washington for the clinical lab community that brings national leaders in the diagnostic sector together with lawmakers and administration officialsContinue Reading »...
